本帖最后由 老马 于 2012-1-13 21:20 编辑 : p- w- A2 z+ _9 e! l% `
) C5 f' b# p j: [+ G
爱必妥和阿瓦斯丁的比较/ u/ ~4 r5 W x8 R8 n& c
) F* Q& J6 R, n7 ~5 }http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
0 C: V& S! w& i1 @" D5 n
! h' r0 v( d* P
) E6 R0 }: n; T3 P; Lhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/' ~: I2 n8 G3 H. h9 P
==================================================9 B, R+ r4 x7 C
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)% @6 M) q% F L& `' {0 Y
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.# P% r2 ~1 y$ D" [7 F# r0 h0 ?1 o
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.6 ?5 |" j {4 u" A, {% u* Q
|